NeuBase Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses and Other Current Liabilities

6 Months Ended

Mar. 31, 2020

10. Accrued Expenses and Other Current Liabilities

The Company’s accrued expenses and other current liabilities consisted of the following:


	March 31,		September 30,
	2020		2019
Accrued compensation and benefits	$	16,848	$	34,625
Accrued interest		3,707		10,830
Accrued professional fees		480,923		156,919
Accrued research and development		119,296		88,553
Deferred other income		237,751		-
Other accrued expenses		84,086		114,672
Total	$	942,611	$	405,599